2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Brian A. Van Tine, MD, PhD, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.
Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses collaboration within the sarcoma field and the importance of clinical trials for advancing treatment.
Van Tine believes it is important for physicians in the sarcoma field, especially with uterine leiomyosarcoma and endometrial stromal sarcoma, to work together because their patients do overlap. Additionally, the treatment and surgical outcomes from collaborating would greatly benefit patients.
Van Tine encourages patients to enroll in clinical trials and for physicians to give patients those opportunities. Currently, clinical trials are the standard of care for sarcoma. Van Tine hopes to one day have a standard of care for patients with sarcoma, but to achieve that, patients must enroll on ongoing studies.
Related Content: